BRPI0515319A - análogos de quinolona - Google Patents

análogos de quinolona

Info

Publication number
BRPI0515319A
BRPI0515319A BRPI0515319-0A BRPI0515319A BRPI0515319A BR PI0515319 A BRPI0515319 A BR PI0515319A BR PI0515319 A BRPI0515319 A BR PI0515319A BR PI0515319 A BRPI0515319 A BR PI0515319A
Authority
BR
Brazil
Prior art keywords
quinolone
analogs
quinolone analogs
present
methods
Prior art date
Application number
BRPI0515319-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Jeffrey P Whitten
Fabrice Pierre
Collin Regan
Michael Schwaebe
George Petros Yiannikouros
Michael Jung
Peter Chua
Johnny Y Nagasawa
Original Assignee
Cylene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/149,007 external-priority patent/US7652134B2/en
Application filed by Cylene Pharmaceuticals Inc filed Critical Cylene Pharmaceuticals Inc
Publication of BRPI0515319A publication Critical patent/BRPI0515319A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0515319-0A 2004-09-17 2005-09-16 análogos de quinolona BRPI0515319A (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US61103004P 2004-09-17 2004-09-17
US63860304P 2004-12-22 2004-12-22
US68898605P 2005-06-09 2005-06-09
US68879605P 2005-06-09 2005-06-09
US11/149,007 US7652134B2 (en) 2004-09-17 2005-06-09 Methods for converting quinolone esters into quinolone amides
PCT/US2005/033323 WO2006034113A2 (en) 2004-09-17 2005-09-16 Quinolone analogs as cell proliferation inhibitors

Publications (1)

Publication Number Publication Date
BRPI0515319A true BRPI0515319A (pt) 2008-07-22

Family

ID=35735203

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515319-0A BRPI0515319A (pt) 2004-09-17 2005-09-16 análogos de quinolona

Country Status (11)

Country Link
US (1) US7816406B2 (enExample)
EP (1) EP1802306A2 (enExample)
JP (1) JP2008513485A (enExample)
KR (1) KR100989029B1 (enExample)
AU (1) AU2005286965B2 (enExample)
BR (1) BRPI0515319A (enExample)
CA (1) CA2580749C (enExample)
IL (1) IL181857A0 (enExample)
MX (1) MX2007003282A (enExample)
NZ (1) NZ553746A (enExample)
WO (1) WO2006034113A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1928887B1 (en) 2005-08-05 2014-12-17 Senhwa Biosciences, Inc. Methods of preparing quinolone analogs
US20110112086A1 (en) * 2006-06-08 2011-05-12 Cylene Pharmaceuticals, Inc. Pyridinone analogs
WO2007146831A2 (en) * 2006-06-08 2007-12-21 Cylene Pharmaceuticals, Inc. Quinolone analogs derivatized with sulfonic acid, sulfonate or sulfonamide
DK2061765T3 (en) 2006-09-01 2015-01-26 Senhwa Biosciences Inc Serine-threonine protein kinase AND PARP-MODULATOR
WO2009002870A1 (en) * 2007-06-22 2008-12-31 Cylene Pharmaceuticals, Inc. Methods for treating aberrant cell proliferation disorders
US20080318939A1 (en) * 2007-06-22 2008-12-25 Whitten Jeffrey P Methods for treating ophthalmic disorders
CA2698463A1 (en) * 2007-08-31 2009-08-06 Cylene Pharmaceuticals, Inc. Therapeutic kinase modulators
NZ583878A (en) 2007-09-14 2012-10-26 Vertex Pharma Modulators of ABC transporter and cystic fibrosis transmembrane conductance regulator (CFTR)
KR101601332B1 (ko) * 2007-10-05 2016-03-08 센화 바이오사이언시즈 인코포레이티드 퀴놀론 유사체 및 이와 관련된 방법
WO2011031745A1 (en) 2009-09-09 2011-03-17 Achaogen, Inc. Antibacterial fluoroquinolone analogs
RU2435758C1 (ru) * 2010-07-19 2011-12-10 Государственное образовательное учреждение высшего профессионального образования Волгоградский государственный технический университет (ВолгГТУ) Способ получения этилового эфира 3-оксо-3-(2,6-дихлорпиридин-3-ил) пропановой кислоты
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
BR112016026150B1 (pt) 2014-05-09 2019-11-05 Pimera, Inc. compostos carboxílicos e seu uso na preparação de medicamentos ou composições farmacêuticas para tratar câncer
WO2016137471A1 (en) * 2015-02-26 2016-09-01 Nantpharma, Llc Method for enhanced heparin quality
CN119185322A (zh) 2015-11-20 2024-12-27 生华生物科技股份有限公司 用于治疗癌症的四环喹诺酮类似物组合疗法
US9957282B2 (en) 2015-12-14 2018-05-01 Senhwa Biosciences, Inc. Crystalline forms of quinolone analogs and their salts
ES2959536T3 (es) * 2015-12-14 2024-02-26 Senhwa Biosciences Inc Formas cristalinas de análogos de quinolona y sus sales
JP2020512975A (ja) 2017-03-28 2020-04-30 ピメラ，インク． Ｐｏｌ１阻害剤の新規な結晶形態
EP3752149A4 (en) 2018-02-15 2022-03-02 Senhwa Biosciences, Inc. QUINOLONE ANALOGUES AND THEIR SALTS, COMPOSITIONS AND METHODS OF USE
JP2020189888A (ja) * 2020-08-28 2020-11-26 センワ バイオサイエンシズ インコーポレイテッド キノロン類似体及びその塩の結晶形
IL328679A (en) * 2023-11-28 2026-07-01 Genome Therapeutics Ltd Tetracyclic compounds for use in antibody-drug conjugates for cancer treatment
WO2025242908A2 (en) * 2024-05-24 2025-11-27 Genome Therapeutics Ltd Novel compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2808070A1 (de) * 1978-02-24 1979-08-30 Bayer Ag Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten
DE3267485D1 (en) 1981-02-18 1986-01-02 Nippon Shinyaku Co Ltd Substituted carboxylic acid derivatives
ZA852802B (en) * 1984-04-26 1985-11-27 Abbott Lab Benzoxazolo-quinoline antibacterial compounds
ZA852769B (en) * 1984-04-26 1985-11-27 Abbott Lab Benzothiazolo-quinoline antibacterial compounds
US4528285A (en) 1984-04-26 1985-07-09 Abbott Laboratories Methylenedioxy quino-benzothiazine derivatives
WO1989012055A1 (fr) 1988-06-08 1989-12-14 Kyorin Pharmaceutical Co., Ltd. Agent antitumoral
US4959363A (en) * 1989-06-23 1990-09-25 Sterling Drug Inc. Quinolonecarboxamide compounds, their preparation and use as antivirals.
IE912902A1 (en) 1990-08-24 1992-02-26 Abbott Lab Quinbenzoxazine, quinobenzothiazine, and pyrido-acridine¹antineoplastic agents
JPH04117388A (ja) * 1990-09-07 1992-04-17 Hokuriku Seiyaku Co Ltd チアゾロキノリン―４―カルボン酸誘導体
US5646163A (en) * 1992-10-30 1997-07-08 The Procter & Gamble Company Quinolone 5-(N-heterosubstituted amino) antimicrobials
GB9402275D0 (en) * 1994-02-07 1994-03-30 Fujisawa Pharmaceutical Co Quinoline derivatives
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6699989B1 (en) 2000-08-28 2004-03-02 B. Vithal Shetty Antiviral and antimicrobial guanidine or biguanidine derivatives
ATE304539T1 (de) 2000-12-14 2005-09-15 Procter & Gamble Antimikrobielle chinolone
US6821969B2 (en) * 2001-02-13 2004-11-23 Pharmacia & Upjohn Company Thioxazinoquinolones as antiviral agents
US6900224B2 (en) 2002-07-31 2005-05-31 The Procter & Gamble Company Antimicrobial quinolones, their compositions and uses
JP2006522827A (ja) 2003-04-07 2006-10-05 サイリーン ファーマシューティカルズ インコーポレーティッド 置換キノベンゾオキサジン類似体
ATE451924T1 (de) 2004-03-15 2010-01-15 Sunesis Pharmaceuticals Inc Sns-595 und anwendungsverfahren

Also Published As

Publication number Publication date
KR20070085264A (ko) 2007-08-27
KR100989029B1 (ko) 2010-10-25
US20060074089A1 (en) 2006-04-06
AU2005286965A1 (en) 2006-03-30
CA2580749C (en) 2014-01-28
AU2005286965B2 (en) 2009-10-22
MX2007003282A (es) 2007-10-16
JP2008513485A (ja) 2008-05-01
EP1802306A2 (en) 2007-07-04
WO2006034113A2 (en) 2006-03-30
IL181857A0 (en) 2007-07-04
US7816406B2 (en) 2010-10-19
CA2580749A1 (en) 2006-03-30
WO2006034113A3 (en) 2006-08-24
NZ553746A (en) 2010-06-25

Similar Documents

Publication Publication Date Title
NL301145I2 (nl) Tirbanibulin
BR112012008385A2 (pt) inibidores de p13 cinase e uso dos mesmos.
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
ECSP099027A (es) Anticuerpos anti-dll4 y métodos que los usan
ECSP088543A (es) Anticuerpos anti-ox40l y métodos que los utilizan
BR112013008140A2 (pt) "compostos imidazotriazinona".
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
CR9786A (es) Compuestos de bencimidazol-tiofeno
NI200900093A (es) Compuestos que modulan la actividad de c-fms y/o c-kit y uso de los mismos.
BRPI0710521A2 (pt) quinazolinas para inibição de pdk1
WO2006034113A3 (en) Quinolone analogs as cell proliferation inhibitors
DK1934174T3 (da) Azetidiner som MEK inhibitorer til behandling af proliferative sygdomme
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
EA200701192A1 (ru) Антагонисты toll-подобного рецептора 3, способы их получения и применение
BRPI0615270A2 (pt) pirazol fundido como inibidores de p38 map cinase
MX2010003685A (es) Analogos de quinolona y metodos relacionados con los mismos.
NO20072179L (no) Kombinasjon av en SRC kinase inhibitor og en. BCR-ABL inhibitor for behandling av proleferative sykdommer
IL176142A0 (en) Processes for preparing montelukast sodium
ATE497492T1 (de) Reinigung von montelukast
SV2006002232A (es) Inhibidores bace ref. x-16940
ECSP088743A (es) Anticuerpos para egfl7 y métodos para su uso
TW200731974A (en) Transdermal system for verenicline
WO2007146813A3 (en) Pyridinone analogs as cell proliferation inhibitors
WO2008060693A3 (en) Tetracyclic imidazole analogs

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.